S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
S&P 500   5,137.08 (+0.80%)
DOW   39,087.38 (+0.23%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
NASDAQ:PETS

PetMed Express (PETS) Stock Price, News & Analysis

$5.01
-0.05 (-0.99%)
(As of 03/1/2024 ET)
Today's Range
$4.96
$5.09
50-Day Range
$5.05
$7.58
52-Week Range
$4.96
$18.81
Volume
277,238 shs
Average Volume
382,313 shs
Market Capitalization
$105.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.25

PetMed Express MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
164.5% Upside
$13.25 Price Target
Short Interest
Bearish
20.74% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.63mentions of PetMed Express in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
900.00%
From $0.01 to $0.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.75 out of 5 stars

Retail/Wholesale Sector

111th out of 208 stocks

Drug Stores & Proprietary Stores Industry

3rd out of 4 stocks


PETS stock logo

About PetMed Express Stock (NASDAQ:PETS)

PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds, PetCare Rx, and PetMeds brands. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.

PETS Stock Price History

PETS Stock News Headlines

3 Oversold Stocks Presenting a Value Opportunity
PetMed Express Inc.
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Pet Wellness Plans for February 2024
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Jim Simons Bolsters Position in PetMed Express Inc
Q3 2023 Petmed Express Inc Earnings Call
A Preview Of PetMed Express's Earnings
Is Ant Spray Safe for Pets?
5 Best Dog Food Brands for Small Breeds
PetMed Express Appoints Leslie Campbell As Chairman
PetMeds® Announces new Chairman of the Board
See More Headlines
Receive PETS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PetMed Express and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
3/01/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/20/2024

Industry, Sector and Symbol

Industry
Drug stores & proprietary stores
Sub-Industry
Internet Retail
Current Symbol
NASDAQ:PETS
CUSIP
71638210
Employees
302
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$13.25
High Stock Price Target
$20.00
Low Stock Price Target
$6.50
Potential Upside/Downside
+164.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$230,000.00
Pretax Margin
-2.38%

Debt

Sales & Book Value

Annual Sales
$270.52 million
Cash Flow
$0.52 per share
Book Value
$5.87 per share

Miscellaneous

Free Float
20,386,000
Market Cap
$105.95 million
Optionable
Optionable
Beta
0.74

Social Links

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Mathew N. Hulett (Age 53)
    CEO, President & Director
    Comp: $534.12k
  • Ms. Christine Chambers (Age 46)
    CFO, Principal Financial Officer, Principal Accounting Officer, Treasurer & Secretary
    Comp: $305.4k
  • Mr. Mark Moseley
    Chief Technology & Information Officer
  • Mr. Daniel Job Pingree
    Chief Marketing Officer
  • Ms. Jacqueline Smith
    Vice President of People
  • Wendy Zalai
    Corporate Controller & Corporate Secretary














PETS Stock Analysis - Frequently Asked Questions

Should I buy or sell PetMed Express stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetMed Express in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PETS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PETS, but not buy additional shares or sell existing shares.
View PETS analyst ratings
or view top-rated stocks.

What is PetMed Express' stock price target for 2024?

2 brokerages have issued 1 year price objectives for PetMed Express' stock. Their PETS share price targets range from $6.50 to $20.00. On average, they anticipate the company's stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 164.5% from the stock's current price.
View analysts price targets for PETS
or view top-rated stocks among Wall Street analysts.

How have PETS shares performed in 2024?

PetMed Express' stock was trading at $7.56 on January 1st, 2024. Since then, PETS shares have decreased by 33.7% and is now trading at $5.01.
View the best growth stocks for 2024 here
.

When is PetMed Express' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our PETS earnings forecast
.

How were PetMed Express' earnings last quarter?

PetMed Express, Inc. (NASDAQ:PETS) announced its quarterly earnings data on Monday, October, 30th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.18 by $0.09. The firm earned $71 million during the quarter, compared to analysts' expectations of $77.13 million. PetMed Express had a negative net margin of 2.25% and a positive trailing twelve-month return on equity of 0.93%. During the same period in the previous year, the business earned $0.13 earnings per share.

How often does PetMed Express pay dividends? What is the dividend yield for PetMed Express?

PetMed Express announced a quarterly dividend on Monday, July 31st. Stockholders of record on Monday, August 14th will be given a dividend of $0.30 per share on Friday, August 18th. This represents a $1.20 annualized dividend and a yield of 23.95%. The ex-dividend date of this dividend is Friday, August 11th.
Read our dividend analysis for PETS
.

Is PetMed Express a good dividend stock?

PetMed Express (NASDAQ:PETS) pays an annual dividend of $0.90 per share and currently has a dividend yield of 0.00%.
Read our dividend analysis for PETS.

What ETFs hold PetMed Express' stock?

ETFs with the largest weight of PetMed Express (NASDAQ:PETS) stock in their portfolio include Formidable ETF (FORH), Amplify Online Retail ETF (IBUY), Global SuperDividend US ETF (DIV) and ProShares Pet Care ETF (PAWZ).Global X E-Commerce ETF (EBIZ).

What guidance has PetMed Express issued on next quarter's earnings?

PetMed Express updated its third quarter 2024 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $65.3 million-$65.3 million, compared to the consensus revenue estimate of $68.0 million.

What is Mendo Akdag's approval rating as PetMed Express' CEO?

5 employees have rated PetMed Express Chief Executive Officer Mendo Akdag on Glassdoor.com. Mendo Akdag has an approval rating of 46% among the company's employees. This puts Mendo Akdag in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of PetMed Express own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetMed Express investors own include Intel (INTC), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Verizon Communications (VZ), Netflix (NFLX) and Micron Technology (MU).

Who are PetMed Express' major shareholders?

PetMed Express' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.57%), Hotchkis & Wiley Capital Management LLC (3.49%), Dimensional Fund Advisors LP (2.75%), Charles Schwab Investment Management Inc. (2.02%), Allianz Asset Management GmbH (1.18%) and Invenomic Capital Management LP (1.02%). Insiders that own company stock include Bruce S Rosenbloom, Christine Chambers, Gian Fulgoni and Mathew N Hulett.
View institutional ownership trends
.

How do I buy shares of PetMed Express?

Shares of PETS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PETS) was last updated on 3/1/2024 by MarketBeat.com Staff